ACG

ACG 2024: GLP-1RAs may reduce pancreatic cancer risk in patients with T2DM

November 7, 2024

GLP-1 receptor agonists (GLP-1 RAs) are associated with a significant reduction in the risk of pancreatic cancer in drug-naive patients with type 2 diabetes (T2DM), according to findings presented at the American College of Gastroenterology annual meeting.

Researchers analyzed deidentified electronic health records from the TriNetX database, focusing on patients with T2DM (N = 4,950,000) who were prescribed various antidiabetic medications between 2005 and 2020. The study compared the incidence of pancreatic cancer in patients treated with GLP-1 RAs with those treated with other antidiabetic therapies, using propensity score matching to control for various factors.

Key findings: Patients on GLP-1 RAs had a significantly lower risk of developing pancreatic cancer compared with those on insulin (hazard ratio, [HR] 0.56), DPP-4 inhibitors (HR 0.80), SGLT2 inhibitors (HR 0.78), and sulfonylureas (HR 0.84). This reduced risk was consistent in both obese and non-obese patients, highlighting the potential of GLP-1 RAs in cancer prevention.

Source:

Alchirazi, K, et al. (2024, October 29). GLP-1 Receptor Agonists and Pancreatic Cancer Risk in Drug-Naive Patients With Type 2 Diabetes. Presented at the American College of Gastroenterology. https://acg2024.eventscribe.net/fsPopup.asp?PresentationID=1498125&mode=presInfo